Pathogenesis of cancers derived from thyroid follicular cells

Nat Rev Cancer. 2023 Sep;23(9):631-650. doi: 10.1038/s41568-023-00598-y. Epub 2023 Jul 12.

Abstract

The genomic simplicity of differentiated cancers derived from thyroid follicular cells offers unique insights into how oncogenic drivers impact tumour phenotype. Essentially, the main oncoproteins in thyroid cancer activate nodes in the receptor tyrosine kinase-RAS-BRAF pathway, which constitutively induces MAPK signalling to varying degrees consistent with their specific biochemical mechanisms of action. The magnitude of the flux through the MAPK signalling pathway determines key elements of thyroid cancer biology, including differentiation state, invasive properties and the cellular composition of the tumour microenvironment. Progression of disease results from genomic lesions that drive immortalization, disrupt chromatin accessibility and cause cell cycle checkpoint dysfunction, in conjunction with a tumour microenvironment characterized by progressive immunosuppression. This Review charts the genomic trajectories of these common endocrine tumours, while connecting them to the biological states that they confer.

Publication types

  • Review
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Oncogene Proteins / metabolism
  • Proto-Oncogene Proteins B-raf / genetics
  • Proto-Oncogene Proteins B-raf / metabolism
  • Receptor Protein-Tyrosine Kinases / metabolism
  • Signal Transduction
  • Thyroid Epithelial Cells* / metabolism
  • Thyroid Epithelial Cells* / pathology
  • Thyroid Neoplasms* / genetics
  • Thyroid Neoplasms* / metabolism
  • Thyroid Neoplasms* / pathology
  • Tumor Microenvironment / genetics

Substances

  • Receptor Protein-Tyrosine Kinases
  • Oncogene Proteins
  • Proto-Oncogene Proteins B-raf